In this video, Kenneth Anderson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the future treatment of myeloma and his presentation at COMy 2022. Dr Anderson highlights his presentation which covered a variety of topics, including novel technologies used to monitor myeloma, the application of therapeutic agents, advances in immunotherapy, and novel targets. Dr Anderson then goes on to discuss precision medicine and the role of novel immunotherapies, including chimeric antigen receptor T-cell (CAR-T) therapy, antibodies, bispecific T-cell engagers (BiTEs), and the importance of achieving measurable residual disease (MRD) negativity. To conclude, Dr Anderson addresses the possibility of achieving cure in myeloma by 2030. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

свернуть